Skip to main content
Quest Diagnostics

Improving the success rate of a challenging RNA-based Next Generation Sequencing (NGS) fusion assay for formalin-fixed paraffin-embedded (FFPE) tissue

Association for Molecular Pathology Annual Meeting
AMP 2022

Phoenix, AZ, Nov  1 - 5, 2022

Poster presentation: Improving the success rate of a challenging RNA-based Next Generation Sequencing (NGS) fusion assay for formalin-fixed paraffin-embedded (FFPE) tissue

Authors: Champion K, Lemoine B, Alderete K, Graham J, Saquib S, Tigh A

Specialties: Genetics, Oncology

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.